In an ambitious pharmacokinetic (PK) study we assessed circulating systemic estrogens in breast cancer (BC) patients on a non-steroidal aromatase inhibitor (NSAI) after insertion of Gynoflor® in vagina affected by severe atrophy [5]. Here, CYP19A1 is linked to breast cancer.